Lilly’s Ascidian Bet and NewLimit’s ‘Anti-Aging’ $3B Valuation Show Biotech’s Newest Obsession: Rewriting Biology Itself -( $COIN $LLY $XBI )

The market is rewarding platforms that promise to rewrite instructions rather than merely manage symptoms. Eli Lilly and Company (LLY) is teaming up with privately held Ascidian Therapeutics in a deal valued at up to $1.9 billion, giving Lilly exclusive, target-specific rights to Ascidian’s RNA exon-editing technology for undisclosed kidney disease targets. That matters because RNA editing offers a different kind of elegance: it aims to correct faulty RNA without permanently changing DNA, which gives the science a cleaner narrative and, at least in theory, a less permanent risk profile. Wall Street tends to like its miracles to come with footnotes, and this one arrives with a fairly thick stack of them.

Why Lilly Is Buying Optionality

For Lilly (LLY), the Ascidian deal is less a moonshot than a portfolio extension. The company is using its balance sheet to buy a place in genetic medicine while keeping the target set narrow enough to feel disciplined and broad enough to matter. That is classic large-cap biotech behavior: pay up for a new modality, keep the first indication focused, and preserve the right to look smart later. In that sense, kidney disease is the perfect opening act—serious enough to justify conviction, but still small enough to let the science earn the standing ovation.

NewLimit And The Age Trade

NewLimit, a privately held longevity startup co-founded by Coinbase Global, Inc. (COIN) CEO Brian Armstrong, has raised $435 million at a valuation north of $3 billion. The company has indicated plans to push its first drug candidate toward the clinic around 2027, aiming initially at age-linked disease while keeping the broader anti-aging thesis firmly in the spotlight. That is a very biotech way to say “start with something testable, then work your way toward the grander dream.” The anti-aging pitch has always needed a respectable bridge to the clinic, and NewLimit is trying to build one with enough capital to make the construction crew sweat.

What Investors Are Buying

Both deals point to the same investor logic: platform science with a believable path to human data remains one of the most magnetic themes in life sciences. Ascidian offers the possibility of rewriting disease at the RNA level, while NewLimit is selling the more audacious idea that cellular aging can be reprogrammed in a clinically useful way. The attraction is not just the science; it is the asymmetry. If these bets work, they could open new therapeutic categories for giants like Lilly (LLY) and create entirely new franchises around longevity. If they do not, the companies still leave behind technology, tools, and perhaps a few bruised PowerPoint decks.

The Sources

1. BioPharma Dive – “Lilly, Ascidian link up in RNA exon editing pact”
   https://www.biopharmadive.com/news/ascidian-lilly-kidney-deal-rna-exon-editing/821749/
2. PR Newswire – “Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Inherited Kidney Diseases”
   https://www.prnewswire.com/news-releases/ascidian-and-lilly-enter-global-research-collaboration-to-develop-rna-exon-editors-for-inherited-kidney-diseases-302174751.html
3. Bloomberg – “Lilly, Ascidian Strike RNA-Editing Pact For Up to $1.9 Billion”
   https://www.bloomberg.com/news/articles/2026-06-03/lilly-ascidian-strike-rna-editing-pact-for-up-to-1-9-billion
4. BioSpace – “Lilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9B”
   https://www.biospace.com/deals/lilly-targets-kidney-disease-with-ascidians-rna-exon-editors-for-up-to-1-9b
5. Axios Pro Biotech Deals – “Ascidian lands up to $1.9B Eli Lilly partnership: Kidney disease RNA editing”
   https://www.axios.com/pro/biotech-deals/2026/06/03/ascidian-2b-eli-lilly-partnership-kidney-disease-rna-editing
6. X (Twitter) – Andrew Dunn post on NewLimit raise
   https://x.com/AndrewE_Dunn/status/2061868784873246787
7. Instagram (Traded VC) – NewLimit funding and valuation post
   https://www.instagram.com/p/DZGWqW_kXZ3/
8. Coinpedia – “Coinbase Co-Founder’s Longevity Startup NewLimit Raises $435M for Human Trials”
   https://coinpedia.org/crypto-live-news/coinbase-co-founders-longevity-startup-newlimit-raises-435m-for-human-trials/